# 06. Developing new regimen for MDR-TB treatment

**Thursday, 30 October 2014, 12:45-14:15**

**Chairs:** Christoph Lange (Germany), Andrew Nunn (USA)  
**Section:** Tuberculosis

| OAP-240-30 | Cost effectiveness of bedaquiline for the treatment of multidrug-resistant tuberculosis  
12:45-12:55 | L Wolfson, R Hettle, A Walker, X Lu, C Kambili, A Murungi, G Knerer (**Belgium, USA, UK**) |
| OAP-241-30 | High rate of successful outcome of a nine-month standardised treatment of multidrug-resistant tuberculosis in Niger  
| OAP-242-30 | Effect of acquired resistance to second line anti-TB drugs on treatment outcomes among multidrug-resistant (MDR-TB) patients from eastern Europe  
| OAP-243-30 | Efficacy and safety of MDR-TB clofazimine containing regimen: the Brazilian cohort experience  
| OAP-244-30 | Preliminary results with a 9-month regimen for multidrug-resistant tuberculosis (MDR-TB) in francophone Africa  
| OAP-245-30 | Discrepancies between Xpert MTB/RIF rifampicin resistant results and confirmatory tests  
13:35-13:45 | E Ardizzoni, C Hewison, R Dela Tour, E Sanchez, A Van Deun, F Varaine, B De Jong (**Belgium, France**) |
| OAP-246-30 | Unacceptable treatment outcomes among India’s initial cohorts of MDR-TB programme  
| OAP-247-30 | Treatment of drug-resistant pulmonary tuberculosis: the clinical effectiveness and tolerability of fluoroquinolones including gemifloxacin  
13:55-14:05 | V Petrenko, G Radysh, V Krasiuk, N Rybak, T Flanigan (**USA**) |

14:05-14:15  
**Discussion**